key: cord-0833882-r1uqhtso authors: Serazin, Nathan A.; Edem, Bassey; Williams, Sarah R.; Ortiz, Justin R.; Kawade, Anand; Kumar Das, Manoj; Šubelj, Maja; Edwards, Kathryn M.; Parida, Shreemanta K.; Anh Wartel, T.; Munoz, Flor M.; Bastero, Patricia title: Acute Respiratory Distress Syndrome (ARDS) as an Adverse Event Following Immunization: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data date: 2021-01-28 journal: Vaccine DOI: 10.1016/j.vaccine.2021.01.053 sha: 72f8b1cb37894e6d817c29126776545b4425b9f0 doc_id: 833882 cord_uid: r1uqhtso This is a Brighton Collaboration Case Definition of the term “Acute Respiratory Distress Syndrome - ARDS” to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission. The comments of the reviewers were taken into consideration and edits incorporated in this final manuscript. heterogeneous areas of pulmonary edema and atelectasis that cause mismatch of lung ventilation and blood perfusion (V/Q mismatch) and hypoxemia. In the proliferative phase, there is proliferation of fibroblasts, myofibroblasts, and locally generated pluripotent mesenchymal progenitor cells that begin the repair process. This response marks the proliferative phase. Endothelial and progenitor cell proliferation restore endothelial barrier function [38] . In the fibrotic phase, expression of multiple pro-fibrotic mediators (e.g., PDGF, TGF-β, IGF-1 etc.) results in dramatic expansion and differentiation of resident fibroblasts into highly synthetic myofibroblasts [39] . This final phase of ARDS may not occur in all patients. While the understanding of ARDS has improved over time, accurate diagnosis remains a challenge. The gold standard diagnostic test is histopathology, which is infeasible in most clinical settings. Furthermore, reliable biomarkers of ARDS remain elusive [40, 41] . As a result, diagnosis remains largely based on clinical criteria that focus on recognizing an acute primary pulmonary illness with diffuse parenchymal involvement and hypoxemia. The Berlin Definition of ARDS has achieved widespread use globally, and it has been recommended for use by the World Health Organization (WHO) and many professional societies [5] . The Berlin Definition criteria consist of 1) new or worsening respiratory symptoms within one week of an inciting clinical insult; 2) chest radiograph or computed tomography (CT) scan showing bilateral infiltrates not fully explained by effusions, pulmonary or lobar collapse, or pulmonary nodule; 3) cardiogenic edema ruled out as an etiology of pulmonary edema; and 4) ratio of arterial partial pressure of oxygen (PaO 2 ) to fraction 6 of inspired oxygen (FiO 2 ), called the P/F ratio, of at most 300 mmHg and positive end-expiratory pressure (PEEP) of at least 5 cm H 2 O [5] . While ARDS has a similar constellation of clinical findings in children, there is growing recognition that there are important clinical and pathologic differences between the two groups [42] . This is evidenced by the fact that direct application of the Berlin Definition to a pediatric population may miss up to 50% of cases as it requires a PaO 2 for case definition [43] . To address this limitation, a separate pediatric definition for ARDS, the Pediatric Acute Lung Injury Consensus Conference (PALICC) Definition was developed. It uses similar criteria including onset after an inciting factor, radiographic abnormalities not caused by cardiogenic edema, and hypoxemia. However, bilateral infiltrates are not required to make a diagnosis; instead, any parenchymal abnormality on chest radiograph is sufficient. Lastly, preference is given to the use of oxygenation index (OI) or oxygenation saturation index (OSI) to quantify the degree of hypoxemia rather than the P/F ratio for intubated pediatric patients. Diagnosis requires an OI ≥ 4 or OSI of ≥ 5. Alternatively, for non-intubated patients requiring ≥ 5 cm H 2 0 of continuous positive airway pressure (CPAP), hemoglobin oxygen saturation (SpO 2 ) to fraction of inspired oxygen (FiO 2 ), called the S/F ratio, may be used. In this case, an S/F of ≤ 264 is required to make the diagnosis. A modification of the Berlin Definition has been advocated for diagnosis of ARDS in resource-limited settings. In this "Kigali modification of the Berlin Definition" of ARDS [24, 44] , named for the city in Rwanda where it was first used, the criteria for timing and origin of edema are kept the same, but a diagnosis can be made in the absence of mechanical or non-invasive positive-pressure 7 ventilation (NIPPV), PaO 2 measurement, or chest CT scan. The Kigali Definition criteria regarding timing, imaging, etiology, and oxygenation are the following: 1) new or worsening respiratory symptoms within one week of an inciting clinical insult; 2) chest radiograph or pulmonary ultrasound showing bilateral infiltrates not fully explained by effusions, pulmonary or lumbar collapse, or pulmonary nodule; 3) cardiogenic edema ruled out as an etiology of pulmonary edema; and 4) S/F ratio of at most 315 in adults. The S/F ratio has been validated as a surrogate for P/F ratio, and is commonly used in research studies of ARDS in high and low resource settings [45] . In addition to the application of diagnostic criteria, clinicians often make several other considerations in the evaluation of ARDS (Table 3) . A physical exam is generally non-specific, but the expected findings include evidence of respiratory distress, hypoxemia, and presence of coarse or diminished breath sounds bilaterally. Notably, a physical exam should also be used to help exclude alternative diagnoses to ARDS. For example, peripheral edema, presence of a third heart sound (S3), and jugular venous reflux would provide evidence in support of a cardiogenic cause of the patient's respiratory process. ARDS can result from a number of different clinical insults. These are typically categorized as either resulting from direct lung injury (such as pneumonia) or indirect lung injury (such as sepsis). Table 4 shows a variety of more common and less common clinical insults of each type. Further, while a patient may meet imaging and oxygenation criteria for ARDS as a result of a pre-existing condition (e.g., 8 cyanotic heart disease) at baseline, this does not exclude the patient from being diagnosed with ARDS. However, the clinical status must represent an acute change from baseline, such as new imaging findings and worsening hypoxemia. While the PaO 2 measurement is the only laboratory value included by the Berlin and PALICC Definitions, clinicians may find several other laboratory tests useful during the evaluation of ARDS to investigate alternative and additional diagnoses, underlying etiologies, and sequelae. For example, studies to evaluate cardiac disease or pulmonary embolism may be useful depending on the clinical context. Laboratory tests may help identify an etiology for ARDS, such as a white blood cell count and microbiologic studies to assess for infection, and lipase to evaluate for pancreatitis. As noted in the imaging component of ARDS consensus definitions, the presence of bilateral infiltrates on chest radiograph or CT scan are required for the diagnosis of ARDS in adults, whereas any infiltrate on chest radiograph is sufficient for the diagnosis in pediatric patients. In the absence of these imaging modalities, lung ultrasound can be considered, and per the Kigali modification of the Berlin Definition, imaging criteria would be met in the presence of B-lines without evidence of effusion in at least one field on each side of the chest in adults [24] . Ultrasound has been an increasingly used imaging modality in the evaluation of patients with respiratory disease and has been found to be sensitive and specific in ARDS [47] . An additional imaging modality that may be employed in the evaluation 9 of acute respiratory illness is the transthoracic echocardiogram (TTE) to evaluate cardiogenic causes of edema and left ventricular function. Severity of ARDS is defined by the patient's oxygenation status. In the Berlin Definition, patients with PEEP or CPAP of ≥5 cm H 2 O or greater can be categorized into three different severity groups based on arterial oxygenation. P/F ratio defines mild disease (>200 to ≤300 mmHg), moderate disease (>100 to ≤200 mmHg), and severe disease (≤100 mmHg). Severity category in adults is associated with differential 90-day mortality: 27% for mild disease, 32% for moderate disease, and 45% for severe disease [5] . In contrast to adults, in children the severity of ARDS is first distinguished between those requiring mechanical ventilation and those receiving NIPPV. For patients who are intubated, severity is then classified by calculation of a patient's oxygen index (OI) or oxygen saturation index (OSI). This measurement is the mean airway pressure (MAP) multiplied by FiO 2 , which is then divided by PaO 2 (OI) or SpO 2 (OSI). Comparable to adults, severity is defined as mild, moderate, or severe according to increasing OI or OSI. While these categories do not reliably stratify risk of mortality in between mild and moderate groups, the severe category has a significantly higher risk of in-hospital mortality ( Severe respiratory distress syndrome associated with SARS-CoV-2 infection deserves special consideration given the current pandemic. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) illness was first described in December 2019 in Wuhan, China, and has caused over 1,000,000 deaths worldwide as of October 2020. Clinical illness caused by SARS-CoV-2 infection is designated COVID-19 and can manifest in a range of respiratory illness, including ARDS. In most cases, COVID-19 is milder in children than in adults. However, children with underlying complex medical conditions are at higher risk of ICU admission and developing severe COVID-19, than healthy children, with approximately 38% requiring mechanical ventilation [58] and a 30% incidence of ARDS [59] . Up to 71-74% of the pediatric patients developing COVID-19 ARDS had at least one co-morbidity, and up to almost 30% had two [58, 59] . Obesity, pre-existing respiratory illness, hematologic, oncologic and/or immune disease and existing neurologic diseases were associated with the development of COVID-19 ARDS. Hispanic and African-American adolescents and adults of are at higher risk of COVID-19 ARDS [59] . ARDS can be caused by a variety of different insults, some with direct impact to the lungs and others via a secondary mechanism. Early reports of ARDS in COVID-19 described an inconsistency between the severity of hypoxia and the findings in lung imaging [60] . When compared to ARDS by other viruses they found certain differences, such as lung compliance and laboratory markers, timing of onset of illness, and preliminary histopathology data, questioning the similarities with classic ARDS, its definition, and therefore, the approach to medical treatment. Recent studies, however, suggest that the physiological differences between COVID-19 patients and ARDS from other etiologies are clinically negligible, and some report up to 85% of the ICU patients meeting Berlin Definition criteria, and responding to standardized therapies such as: low tidal volumes ventilation; conservative fluid management, and in some instances, prone ventilation [61, 62] . The presence of ARDS is associated with high mortality risk in adults, and lower probability of hospital discharge in children [59] . We conducted a PubMed search on August 20, 2020, to identify reports of ARDS after any vaccination. The terms used in the search We found 324 articles. A review of the abstracts of these articles revealed that while various infectious diseases are associated with the development of ARDS, there are no reports suggesting a temporal association of ARDS after vaccination with currently licensed vaccines. Actually, a reduction in ARDS has been reported in vaccinated individuals for certain respiratory pathogens, such as influenza [63] . The exception is one case report from 1981, where a case of fatal ARDS occurred in a 15-month-old who had suffered minor scalding after immunization with the live attenuated measles, mumps, and rubella (MMR) vaccine. The report suggests that the scalding suppressed the normal immune response to the measles viremia, which caused the lung damage which, in turn, led to ARDS. According 13 to the report, the lung had fibroblastic nodules, vessel wall inflammation and other signs consistent with ARDS [64] . In the US VAERS reporting system, 124 events of ARDS have been reported following various immunizations, with no data regarding association (https://vaers.hhs.gov/ accessed 14 Dec 2020). The occurrence of possible vaccine associated enhanced disease (VAED), a phenomenon that may present clinically like ARDS but which is distinct in its pathogenesis, was described after administration of formalin-inactivated vaccines against respiratory syncytial virus (RSV) in the 1960's, and some measles, pandemic influenza, and other respiratory virus vaccines [65] . In a recent summary of key findings in non-human primates and phase I/II studies of the most advanced SARS-CoV-2 vaccine candidates [66] , there was no evidence for COVID-19 enhanced disease either based on antibody dependent enhancement or on enhanced infiltration of eosinophils into the lung upon infection post-immunization. Clinical data have shown acceptable safety and reactogenicity profiles across different vaccine candidate platforms, production of varying neutralizing antibody titers, and some vaccine candidates also elicited T-cell responses. However, additional long-term monitoring of persons exposed to SARS-CoV-2 vaccines is required in pre-and post-licensure stages to determine the risk of vaccine associated disease enhancement, particularly once neutralizing antibody titers start to wane [67] . The Working Group evaluated existing definitions of ARDS and developed a case definition for the assessment of ARDS as a potential adverse event following any immunization. Within this definition, a level of diagnostic certainty is ascribed based on the quality of evidence to support the criteria used to make the diagnosis. The Level 1 definition is highly specific for ARDS. As maximum specificity normally implies a loss of sensitivity, we included two additional diagnostic levels in the definition, offering a stepwise increase in sensitivity from Level 1 down to Level 3, while retaining an acceptable specificity at all levels. In addition, the case definition also allows for characterization of severity as mild, moderate, or severe based on the degree of hypoxemia. This was included to align the case definition with existing definitions for ARDS. However, the three levels of certainty must not be misunderstood as reflecting different groups grades of clinical severity. While standard definitions of ARDS include consideration for timing between insult and the onset of respiratory findings, our definition does not prescribe a specified time between vaccination and the onset of ARDS, as long as all other criteria for diagnosis are fulfilled. However, a temporal association consistent with the expected clinical course of ARDS would be suggested by a typical interval of one to two weeks between the insult and ARDS. Therefore, when considering the possibility of ARDS as an adverse event following immunization it is unlikely that ARDS would occur months after the exposure. Therefore, in application of this definition, special consideration must be given to how details of this interval are collected and reported. definition. A treatment response or its failure is not in itself diagnostic and may depend on variables like clinical status, time to treatment, and other clinical parameters. The case definition is not meant to determine causality, and, therefore, known causes of ARDS should be evaluated (see Table 4 ). The case definition is accompanied by guidelines which are structured according to the steps of conducting a clinical trial, i.e., data collection, analysis and presentation (Appendix A). Neither case definition nor guidelines are intended to be used for management of ill infants, children, or adults. Review of the definition with its guidelines is planned on a regular basis and as needed. Because ARDS is a heterogeneous disease process, diagnostic accuracy under typical circumstances is imperfect [68] . Furthermore, case definitions that require positive pressure or mechanical ventilation, chest imaging, and blood gas analyses pose barriers to diagnosis in resource-limited settings [69] . To address these concerns, the working group developed diagnostic criteria that are stratified according to level of certainty as summarized in Table 5 and Figure 1 . These levels reflect the accuracy of the evidence to support the diagnosis. 16 Levels of certainty include confirmed ARDS (Level 1), probable ARDS (Level 2), and suspected ARDS (Level 3). In addition, Level 4 defines cases with insufficient data to make the diagnosis, and Level 5, cases for which there is sufficient data to attribute ARDS to another cause (i.e., not a case of ARDS). Confirmed cases of ARDS (Level 1) are reserved for patients that meet the criteria set forth by the Berlin Definition for adults and PALICC Definition for pediatrics. These criteria represent the most widely accepted clinical criteria used to diagnose ARDS in adults and children, respectively. While the working group gave consideration to a single set of criteria, evidence supports that this would lead to missed cases [33] , and therefore, we developed separate adult and pediatric criteria. Consistent with the standard ARDS definitions which were derived from heterogenous data sets that used variable age cutoffs, we do not provide guidance on age cutoffs for each. While the Berlin and PALICC Definitions are the most widely used criteria, there are limitations to each that result in potential missed cases of ARDS [49] . To address this, alternative criteria were reviewed and included to define probable (Level 2) and suspected (Level 3) cases of ARDS. The relevant clinical scenarios are those without access to blood gas analysis, settings without radiographs or computed tomography scans, or patients not supported with positive pressure ventilation (PPV). For Level 2, or probable ARDS, the relevant considerations are access to arterial blood gas analysis and chest imaging, which are used to subdivide the group into levels 2a and 2b. Level 2a is applicable in settings without access to arterial blood gases and uses an S/F rather than P/F ratio. While the discriminatory power of S/F to predict mortality with mild/moderate cases is inferior to P/F, it is comparable in severe cases [49, 70] . Furthermore, it accurately predicts increasing mortality with worsening hypoxemia. In comparison, Level 2b definition is applicable to clinical settings where chest radiograph or CT scans are unavailable. While typically thought of as an adjunct to routine imaging, chest ultrasound is becoming increasingly common, and has been shown to accurately identify ARDS in both adult and pediatric populations [8, 71] . Although data are inconclusive regarding chest ultrasound equivalence to routine imaging, there are sufficient data to merit its inclusion as an alternative imaging modality [72] . Note that for Level 2 cases and below, PPV is not a requirement to meet the case definition for ARDS. Given that high-flow nasal cannula support is becoming increasingly common, especially as an alternative form of non-invasive support for patients with ARDS [73] , the working group determined that inclusion of PPV would lead to too many missed cases. This would be especially true in resource-limited settings where access to PPV may be limited. Lastly, because ARDS is a clinical diagnosis, special designation was given to include suspected ARDS (Level 3). In this category, a clinician would make the diagnosis based on a thorough history, physical examination, and characterization of hypoxemia, and then the 18 clinician would make the assessment on a clinical basis alone (Table 3) . This is most relevant in the setting where chest radiograph, CT scan, and ultrasound are unavailable. While it is difficult to estimate the performance of diagnosis based on clinical criteria alone, the working group believes that it is important to include this category while acknowledging the decreased diagnostic certainty, so clinical expertise in limited resource settings is also considered. The diagnosis of ARDS is challenging, especially in patients with pre-existing conditions. For example, patients with cyanotic heart disease or chronic lung disease may meet several criteria for ARDS at baseline. To account for this, the case definition specifies that a patient's clinical presentation must represent an acute change from baseline, which aligns with other criteria for ARDS. Bellani To make diagnosis, must meet ALL of the following criteria: 1) Hypoxemia -P/F Ratio ≤ 300 2) Positive Pressure Requirement: -PEEP/CPAP ≥ 5 cmH20 3) Imaging: Chest imaging with bilateral chest opacities not explained by other process 4) Origin of edema: not related to fluid overload or cardiogenic edema 5) Timing: within 1 week of known clinical insult* PALICC Definition To make diagnosis, must meet ALL of th 1) Hypoxemia -P/F ≤ 300 or S/F ≤ 264 for non-in -OI ≥ 4 or OSI ≥ 5 for intubated pa 2) Positive Pressure Requirement: -PEEP/CPAP ≥ 5cm H20 3) Imaging: Chest imaging findings of with acute pulmonary parenchymal 4) Origin of edema: new infiltrate not cardiogenic edema 5) Timing: within 1 week of known cl Clinical suspicion but insufficient data to Level 5 Not a case of ARDS Patients that do not meet above criteria for ARDS but may have hypoxemia and/or chest imaging findings due to other pathologic process Patients that do not meet above criteria f hypoxemia and/or chest imaging finding process * Timing criteria for ARDS, may vary after vaccination. ^ Severity as defined by S/F: For adults, mild ≤ 315 but >235, moderate ≤ 235 but >144, severe S/F ≤ 144. For pediatrics, mild ≤ 264 but > 221, moderate ≤ 221 but >150, severe S/F ≤ 150 + Strong clinical concern as defined in Table 3 Abbreviations: P/F ratio -PaO 2 to FiO 2 ratio (arterial oxygen pressure to inspired fraction of oxygen ratio); S/F ratio -Saturation by pulse oximeter to FiO 2 ratio; PEEP -positive end expiratory pressure; CPAP -continuous positive airway pressure; CXR -chest x-ray; CT = chest tomography; US = ultrasound; OI = oxygenation index; OSI = oxygen saturation index surveillance or epidemiological study, or an individual report of ARDS. Also, as explained in more detail in the overview paper in this volume, these guidelines have been developed by this working group for guidance only, and are not to be considered a mandatory requirement for data collection, analysis, or presentation. These guidelines represent a desirable standard for the collection of data on availability following immunization to allow for comparability of data and are recommended as an addition to data collected for the specific study question and setting. The guidelines are not intended to guide the primary reporting of ARDS to a surveillance system or study monitor. Investigators developing a data collection tool based on these data collection guidelines also need to refer to the criteria in the case definition, which are not repeated in these guidelines. Guidelines below have been developed to address data elements for the collection of adverse event information as specified in general drug safety guidelines by the International Conference on [74], and the form for reporting of drug adverse events by the Council for International Organizations of Medical Sciences [75] . These data elements include an identifiable reporter and patient, one or more prior immunizations, and a detailed description of the adverse event, in this case, of ARDS following immunization. The additional guidelines have been developed as guidance for the collection of additional information to allow for a more comprehensive understanding of ARDS following immunization. For all cases and/or all study participants, as appropriate, the following information should be recorded: 1) Date of report. 2) Name and contact information of person reporting 1 and/or diagnosing the ARDS as specified by country-specific data protection law. 3) Name and contact information of the investigator responsible for the subject, as applicable. 4) Relation to the patient (e.g., immunizer (clinician, nurse), family member (indicate relationship), other). Demographics For all cases and/or all study participants, as appropriate, the following information should be recorded: 5) Case/study participant identifiers (e.g., first name initial followed by last name initial) or code (or in accordance with country-specific data protection laws). 6) Date of birth, age, and sex. 7) For infants: Gestational age and birth weight. For all cases and/or all study participants, as appropriate, the following information should be recorded: 8) Past medical history, including hospitalizations, underlying diseases/disorders, preimmunization signs and symptoms including identification of indicators for, or the absence of, a history of allergy to vaccines, vaccine components or medications; food allergy; allergic rhinitis; eczema; asthma. 9) Any medication history (other than treatment for the event described) prior to, during, and after immunization including prescription and non-prescription medication as well as medication or treatment with long half-life or long-term effect. (e.g., immunoglobulins, blood transfusion and immunosuppressants). 10) Immunization history (i.e., previous immunizations and any adverse event following immunization (AEFI)), in particular occurrence of ARDS after a previous immunization. For all cases and/or all study participants, as appropriate, the following information should be 25) Exposures other than the immunization 24 hours before and after immunization (e.g., food, environmental) considered potentially relevant to the reported event. 26) The duration of surveillance for ARDS should be predefined based on: • Biologic characteristics of the vaccine (e.g., live attenuated versus inactivated component vaccines); • Biologic characteristics of the vaccine-targeted disease; • Biologic characteristics of ARDS including patterns identified in previous trials (e.g., early-phase trials); and • Biologic characteristics of the vaccinee (e.g., nutrition, underlying disease like immunodepressing illness). 27) The duration of follow-up reported during the surveillance period should be predefined likewise. It should aim to continue to resolution of the event. 28) Methods of data collection should be consistent within and between study groups, if applicable. 29) Follow-up of cases should attempt to verify and complete the information collected as outlined in data collection guidelines 1 to 24. 30) Investigators of patients with ARDS should provide guidance to reporters to optimize the quality and completeness of information provided. 31) Reports of ARDS should be collected throughout the study period regardless of the time elapsed between immunization and the adverse event. If this is not feasible due to the study design, the study periods during which safety data are being collected should be clearly defined. The following guidelines represent a desirable standard for analysis of data on ARDS to allow for comparability of data, and are recommended as an addition to data analyzed for the specific study question and setting. 32) Reported events should be classified in one of the following five categories including the three levels of diagnostic certainty. Events that meet the case definition should be classified according to the levels of diagnostic certainty as specified in the case definition. Events that do not meet the case definition should be classified in the additional categories for analysis. and/or final outcome 6 . Whatever start and ending are used, they should be used consistently within and across study groups. 35) If more than one measurement of a particular criterion is taken and recorded, the value corresponding to the greatest magnitude of the adverse experience could be used as the basis for analysis. Analysis may also include other characteristics like qualitative patterns of criteria defining the event. 36) The distribution of data (as numerator and denominator data) could be analyzed in predefined increments (e.g., measured values, times), where applicable. Increments specified above should be used. When only a small number of cases is presented, the respective values or time course can be presented individually. 37) Data on ARDS obtained from subjects receiving a vaccine should be compared with those obtained from an appropriately selected and documented control group(s) to assess background rates of hypersensitivity in non-exposed populations, and should be analyzed by study arm and dose where possible (e.g., in prospective clinical trials). These guidelines represent a desirable standard for the presentation and publication of data on ARDS following immunization to allow for comparability of data, and are recommended as an addition to data presented for the specific study question and setting. Additionally, it is recommended to refer to existing general guidelines for the presentation and publication of randomized controlled trials, systematic reviews, and meta-analyses of observational studies in epidemiology (e.g., statements of Consolidated Standards of Reporting Trials (CONSORT) [76] , of Improving the quality of reports of meta-analyses of randomized controlled trials (QUOROM) [77], and of Meta-analysis Of Observational Studies in Epidemiology (MOOSE) [78] , respectively). 38) All reported events of ARDS should be presented according to the categories listed in guideline 31. 39) Data on possible ARDS events should be presented in accordance with data collection guidelines 1-24 and data analysis guidelines 31-36. 40) Terms to describe ARDS such as "low-grade", "mild", "moderate", "high", "severe" or "significant" are highly subjective, prone to wide interpretation, and should be avoided, unless clearly defined. 41) Data should be presented with numerator and denominator (n/N) (and not only in percentages), if available. Although immunization safety surveillance systems denominator data are usually not readily available, attempts should be made to identify approximate denominators. The source of the denominator data should be reported, and calculations of estimates be described (e.g., manufacturer data like total doses distributed, reporting through Ministry of Health, coverage/population-based data). 42) The incidence of cases in the study population should be presented and clearly identified as such in the text. 43) If the distribution of data is skewed, median and range are usually the more appropriate statistical descriptors than a mean. However, the mean and standard deviation should also be provided. 44) Any publication of data on ARDS should include a detailed description of the methods used for data collection and analysis as possible. It is essential to specify: • The study design; • The method, frequency and duration of monitoring for ARDS; • The trial profile, indicating participant flow during a study including drop-outs and withdrawals to indicate the size and nature of the respective groups under investigation; • The type of surveillance (e.g., passive or active surveillance); • The characteristics of the surveillance system (e.g., population served, mode of report solicitation); • The search strategy in surveillance databases; • Comparison group(s), if used for analysis; A treatise on the diseases of the chest and on mediate auscultation. 1835 Acute respiratory distress in adults. The Lancet, Saturday 12 An expanded definition of the adult respiratory distress syndrome The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination Acute respiratory distress syndrome: the Berlin Definition The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference Diagnosing acute respiratory distress syndrome in resource limited settings: the Kigali modification of the Berlin definition Incidence and outcomes of acute lung injury Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota Incidence of adult respiratory distress syndrome in trauma patients: A systematic review and meta-analysis over a period of three decades Impact of distinct definitions of acute lung injury on its incidence and outcomes in Brazilian ICUs: prospective evaluation of 7,133 patients* Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation Acute respiratory distress syndrome: nationwide changes in incidence, treatment and mortality over 23 years Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management Incidence of acute respiratory distress syndrome and its relation to age Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States Incidence and Outcomes of Acute Respiratory Distress Syndrome: A Nationwide Registry-Based Study in Taiwan National survey of outcomes and practices in acute respiratory distress syndrome in Singapore Incidence and outcomes of acute respiratory distress syndrome in intensive care units of mainland China: a multicentre prospective longitudinal study Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition Clinical Manifestations and Outcomes of Critically Ill Children and Adolescents with Coronavirus Disease Acute respiratory failure in COVID-19: is it "typical" ARDS? Critical Care Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies Excess mortality is associated with influenza A (H1N1) in patients with severe acute respiratory illness Fatal adult respiratory distress syndrome in a scalded child after immunization with attenuated virus (measles, mumps and rubella) Rapid COVID-19 vaccine development SARS-CoV-2 vaccines in development Vaccine-associated Enhanced Disease: Case Definition and Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data Missed or delayed diagnosis of ARDS: a common and serious problem What's new in ARDS: ARDS also exists in resource-constrained settings The Value of Oxygenation Saturation Index in Predicting the Outcomes of Patients with Acute Respiratory Distress Syndrome The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity Chest radiography versus lung ultrasound for identification of acute respiratory distress syndrome: a retrospective observational study Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study The Council for International Organizations of Medical Sciences. CIOMS I FORM Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group The authors are grateful for the support and helpful comments provided by Robert Chen from the Brighton Collaboration Steering Committee; Barbara Law, Steve Black, Cornelia Decker from SPEAC; as well as experts consulted as part of the process. The authors are also grateful to Matt • The instrument of data collection (e.g., standardized questionnaire, diary card, report form); • Whether the day of immunization was considered "day one" or "day zero" in the analysis;• Whether the date of onset 2 and/or the date of first observation 3 and/or the date of diagnosis 4 was used for analysis; and • Use of this case definition for ARDS, in the abstract or methods section of a publication 11 .Notes for guidelines 1 If the reporting center is different from the vaccinating center, appropriate and timely communication of the adverse event should occur. 2 The date and/or time of onset is defined as the time post immunization, when the first sign or symptom indicative for ARDS occurred. This may only be possible to determine in retrospect. 3 The date and/or time of first observation of the first sign or symptom indicative for ARDS can be used if date/time of onset is not known. 4 The date of diagnosis of an episode is the day post immunization when the event met the case definition at any level. 5 The end of an episode is defined as the time the event no longer meets the case definition at the lowest level of the definition. 6 E.g., recovery to pre-immunization health status, spontaneous resolution, therapeutic intervention, persistence of the event, sequelae, death. 7 An AEFI is defined as serious by international standards if it meets one or more of the following criteria: 1) it results in death, 2) is life-threatening, 3) it requires inpatient hospitalization or results in prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) is a congenital anomaly/birth defect, 6) is a medically important event or reaction. 8 To determine the appropriate category, the user should first establish, whether a reported event meets the criteria for the lowest applicable level of diagnostic certainty (e.g., Level three). If the lowest applicable level of diagnostic certainty of the definition is met, and there is evidence that the criteria of the next higher level of diagnostic certainty are met, the event should be classified in the next category. This approach should be continued until the highest level of diagnostic certainty for a given event could be determined. If the lowest level of the case definition is not met, it should be ruled out that any of the higher levels of diagnostic certainty are met and the event should be classified in additional categories four or five. 9 If the evidence available for an event is insufficient because information is missing, such an event should be categorized as "Reported ARDS with insufficient evidence to meet the case definition". 10 An event does not meet the case definition if investigation reveals a negative finding of a necessary criterion (necessary condition) for diagnosis. Such an event should be rejected and classified as "Not a case of ARDS".